75N91018F00059↗
Leidos Biomedical Research Inc received this contract from Nih Nci, National Institutes of Health: $10.93M obligated so far for operation of government-owned contractor-operated (goco) r&d facilities. It runs to 2028-09-21.
Key facts · data as of Oct 28, 2026
- Recipient
- Leidos Biomedical Research Inc
- Awarding agency
- National Institutes of Health (Department of Health and Human Services)
- Contracting office
- Nih Nci (75N910)
- Obligated to date
- $10.93M
- Potential value
- $56.38M
- Ends
- 2028-09-21
Source: USAspending.gov prime award records (obligations: money committed, not outlays), data as of Oct 28, 2026.
Cite this page: SpendQuery, Award 75N91018F00059, data as of Oct 28, 2026, https://spendquery.com/award?id=CONT_AWD_75N91018F00059_7529_HHSN261201500003I_7529
Leidos Biomedical Research Inc: all federal awards · Department of Health and Human Services: spending · Nih Nci: what it buys · The follow-on: recompete brief
EBOLA VIRUS AND OTHER INFECTIOUS DISEASES
Up for re-bid: ends 2028-09-21. Recompete brief →
What it is
- Product or service
- Operation of Government-Owned Contractor-Operated (Goco) R&D Facilities (PSC M1HA)
- Industry
- Facilities Support Services (NAICS 561210)
- Contracting office
- Nih Nci (75N910)
- Competition
- Not competed
- Pricing
- Cost plus fixed fee
- How it was bought
- Single-award IDIQ · under HHSN261201500003I
- Solicitation
- N01CO5240180
- Where the work is
- Frederick, MD · district MD-06
Obligations by fiscal year
SpendQuery holds FY2023 on; earlier years are on USAspending.gov.
Subcontractors: where the money went next
7 subawards totaling $20.18M (184.7% of what was obligated), as Leidos Biomedical Research Inc reported them. Primes report subawards of $30,000 or more; smaller ones and unreported ones aren't here.
| Subcontractor | Amount | Subawards | Where | First | Last |
|---|---|---|---|---|---|
| Mitchell Group, Inc. (The) | $20.09M | 6 | DC | 2023-05-01 | 2025-08-31 |
| Xator LLC | $85.9K | 1 | VA | 2022-10-03 | 2022-10-03 |
The largest single subawards
| Date | To | Amount | For |
|---|---|---|---|
| 2025-08-31 | Mitchell Group, Inc. (The) | $8.60M | SUBCONTRACTOR WILL BE TASKED TO PROVIDE RAPID DEPLOYMENT OF TECHNICAL, OPERATIONAL, AND CLINICAL RESEARCH RESOURCES AND EXPERTISE FOR THIS TIME-SENSITIVE INITIATIVE. THE PROTOCOL IS TITLED, ASSESSMENT OF IMMUNE… |
| 2024-12-31 | Mitchell Group, Inc. (The) | $7.86M | SUBCONTRACTOR WILL BE TASKED TO PROVIDE RAPID DEPLOYMENT OF TECHNICAL, OPERATIONAL, AND CLINICAL RESEARCH RESOURCES AND EXPERTISE FOR THIS TIME-SENSITIVE INITIATIVE. THE PROTOCOL IS TITLED, ASSESSMENT OF IMMUNE… |
| 2024-08-31 | Mitchell Group, Inc. (The) | $987.3K | SUBCONTRACTOR WILL BE TASKED TO PROVIDE RAPID DEPLOYMENT OF TECHNICAL, OPERATIONAL, AND CLINICAL RESEARCH RESOURCES AND EXPERTISE FOR THIS TIME-SENSITIVE INITIATIVE. THE PROTOCOL IS TITLED, ASSESSMENT OF IMMUNE… |
| 2024-07-10 | Mitchell Group, Inc. (The) | $987.3K | SUBCONTRACTOR WILL BE TASKED TO PROVIDE RAPID DEPLOYMENT OF TECHNICAL, OPERATIONAL, AND CLINICAL RESEARCH RESOURCES AND EXPERTISE FOR THIS TIME SENSITIVE INITIATIVE. THE PROTOCOL IS TITLED, ASSESSMENT OF IMMUNE… |
| 2023-10-21 | Mitchell Group, Inc. (The) | $975.9K | SUBCONTRACTOR WILL BE TASKED TO PROVIDE RAPID DEPLOYMENT OF TECHNICAL, OPERATIONAL, AND CLINICAL RESEARCH RESOURCES AND EXPERTISE FOR THIS TIME-SENSITIVE INITIATIVE. THE PROTOCOL IS TITLED, ASSESSMENT OF IMMUNE… |
| 2023-05-01 | Mitchell Group, Inc. (The) | $683.4K | SUBCONTRACTOR WILL BE TASKED TO PROVIDE RAPID DEPLOYMENT OF TECHNICAL, OPERATIONAL, AND CLINICAL RESEARCH RESOURCES AND EXPERTISE FOR THIS TIME-SENSITIVE INITIATIVE. THE PROTOCOL IS TITLED, ASSESSMENT OF IMMUNE… |
| 2022-10-03 | Incadence Strategic Solutions LLC | $85.9K | THE OBJECTIVE OF THIS REQUEST IS TO PROVIDE RESOURCES NEEDED TO MANAGE AND MAINTAIN A BIOMETRICS PLATFORM USED IN SUPPORT OF CLINICAL RESEARCH STUDIES IN WEST AFRICA. DATA FROM THIS RESEARCH WILL BE USED TO INFORM… |
Every action
11 actions since 2022-12-14. Each is a modification or amendment with the money it added or took back.
| Date | Modification | Kind | Amount | What the agency wrote |
|---|---|---|---|---|
| 2025-09-02 | P00020 | Administrative change | -$8.43M | EOI: IMPLEMENTING THE PRESIDENTS DEPARTMENT OF GOVERNMENT EFFICIENCY COST EFFICIENCY INITIATIVE (MARCH 19, 2025)::EOI. |
| 2025-04-24 | P00019 | Terminated for convenience | $0 | EOI::IMPLEMENTING THE PRESIDENTS DEPARTMENT OF GOVERNMENT EFFICIENCY COST EFFICIENCY INITIATIVE (MARCH 19, 2025)::EOI. |
| 2024-09-23 | P00018 | Administrative change | -$86.6K | EBOLA VIRUS AND OTHER INFECTIOUS DISEASES |
| 2024-08-02 | P00017 | Administrative change | $0 | EBOLA VIRUS AND OTHER INFECTIOUS DISEASES |
| 2024-05-03 | P00016 | Administrative change | $0 | EBOLA VIRUS AND OTHER INFECTIOUS DISEASES |
| 2024-02-13 | P00015 | Administrative change | $0 | EBOLA VIRUS AND OTHER INFECTIOUS DISEASES |
| 2023-10-16 | P00014 | Administrative change | $0 | EBOLA VIRUS AND OTHER INFECTIOUS DISEASES |
| 2023-09-21 | P00013 | Option exercised | $19.44M | EBOLA VIRUS AND OTHER INFECTIOUS DISEASES |
| 2023-09-01 | P00012 | Administrative change | $0 | EBOLA VIRUS AND OTHER INFECTIOUS DISEASES |
| 2023-08-01 | P00011 | Administrative change | $0 | EBOLA VIRUS AND OTHER INFECTIOUS DISEASES |
| 2022-12-14 | P00010 | Administrative change | $0 | EBOLA VIRUS AND OTHER INFECTIOUS DISEASES |
Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-10-28). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗